Drug intelligence / Profile preview

microRNA-323b-5p mimic

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

microRNA-323b-5p mimic is a synthetic RNA oligonucleotide designed to restore the activity of the endogenous microRNA miR-323b-5p, which often functions as a tumor suppressor. In non-small cell lung cancer (NSCLC), miR-323b-5p is frequently downregulated, and its low expression is associated with poor patient prognosis. The mimic operates by binding to the 3' untranslated region (UTR) of the Interleukin 1 Alpha (IL1A) messenger RNA, leading to its degradation or translational inhibition. By reducing IL1A levels, the mimic effectively suppresses cancer cell proliferation and modulates the cell cycle, specifically inducing arrest. This agent is primarily utilized in preclinical research to investigate miRNA-mediated gene regulation and as a potential therapeutic strategy for restoring miRNA-driven growth control in malignancies.

Other names
miR-323b-5pmiR323b-5pmiR 323b-5pmicroRNA-323b-5pmicroRNA323b-5pmicroRNA 323b-5p
02

Targets

IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on microRNA-323b-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA-323b-5p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call